Navigation Links
Willa A. Hsueh, M.D., Joins Bionovo's Scientific Advisory Board
Date:12/15/2008

EMERYVILLE, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Willa Hsueh, M.D., to the company's Scientific Advisory Board. Dr. Hsueh has extensive experience in the design and conduct of clinical trials, basic science research and in pharmaceutical drug development.

"We are very excited to have Dr. Hsueh on the scientific advisory board as we are advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. "Dr. Hsueh is currently the Director of the Diabetes Research Center at The Methodist Hospital Research Institute and Chief of the Division of Diabetes, Obesity and Lipids in the Department of Medicine at The Methodist Hospital (TMHRI), Houston, Texas. Dr. Hsueh's research has led to a number of important scientific discoveries. She was the first to elucidate the relationship between nuclear receptor regulation in obesity and diabetes and their relationship to heart disease. This scientific advancement is especially critical for menopausal women and Dr. Hsueh's research ties into Bionovo's current drug discovery platform as well as our future platform development of drugs for obesity. In addition, Dr. Hsueh's deep relationships in both industry and academia will help Bionovo with our partnership discussions and scientific collaborations."

Dr. Hsueh adds, "I am looking forward to working with Bionovo's exceptional team on their very exciting nuclear receptor discovery platform. The scientific group that has been assembled to collaborate with Bionovo is unmatched in the industry. I believe the very promising pipeline of Bionovo drug candidates will provide new and improved therapies for women."

Dr. Hsueh and her team were the first to identify a potentially protective role for the activation of nuclear receptors of the peroxisome proliferator activated receptor family (PPAR) in vascular injury. Dr. Hsueh was one of the earliest investigators to suggest that diabetes is a major contributor to cardiovascular injury, and she has been dedicated to identifying biomarkers and genetic defects associated with increased risks for diabetes and cardiovascular disease,

Dr. Hsueh has received many awards in recognition of her clinical and scientific work. In 2005 she received the Edwin B. Astwood Award from the Endocrine Society for Outstanding Research. She also received the National Institute of Arthritis, Metabolism and Digestive Diseases, MERIT Award from 1991- 1998, the American Heart Association, Harry Goldblatt Award for Cardiovascular Research in 1986 and The Upjohn Achievement Award for Research in 1973. Prior to becoming the Director of the Diabetes Research Center at The Methodist Hospital Research Institute and Chief of the Division of Diabetes, Obesity and Lipids in the Department of Medicine at The Methodist Hospital (TMHRI), Houston, Texas earlier this year, Dr. Hsueh was the Chief of the Division of Endocrinology, Diabetes and Hypertension at the University of California, Los Angeles (UCLA) from 1997 to 2008. In addition to her academic and administrative duties, Dr. Hsueh maintains a full clinical practice and is involved in many translational research projects.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
4. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
5. William F. Balistreri, M.D., honored with Distinguished Service Award by AASLD
6. Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACCs 57th Annual Scientific Session
7. Pioneering Heart Surgeon, Robert E. Michler, M.D., Appointed Chair of Surgery and Surgeon-in-Chief at Einstein and at Montefiore Medical Center
8. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
9. Dr. Siegals(R) COOKIE DIET(TM) Creator Sanford Siegal, D.O., M.D., Weighs In on Madonnas My husband didnt want to have sex on the cookie diet Remarks
10. Jeff Bailet, M.D., Appointed to American Medical Associations Advisory Committee
11. Statement of Robert OConnor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading provider ... titled “ 5 Questions to Ask Before Entering the Maze of Genetic Testing ... Evaluation (GTE) team, the book explores the various types of the more than ...
(Date:6/20/2017)... ... ... Kenneth Mayer, MD, has been appointed a new Editor-in-Chief of the ... JIAS Editorial Board in 2016, has co-authored more than 800 peer-reviewed publications. Among his ... and Co-Chair of The Fenway Institute, a member of the US President’s Emergency Plan ...
(Date:6/20/2017)... Houston, Texas (PRWEB) , ... June 20, 2017 , ... ... of their new website and a host of new options for today’s modern ... helping seniors maintain the active, independent lifestyle they love while offering them the services ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... for the enterprise, is proud to announce Touchpoints integrations. MindTouch Touchpoints ... company websites, and more to provide a seamless customer experience. , Truly “plug ...
(Date:6/20/2017)... ... 2017 , ... Dr. Manju R. Kejriwal currently accepts new ... or not they have a referral. Dr. Kejriwal offers state-of-the-art treatment through the ... bacteria and damaged tissue without affecting the surrounding tissue. This technology virtually eliminates ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/2/2017)... 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology ... findings demonstrating positive biochemical outcomes related to more frequent ... data will be presented at the ERA-EDTA Congress being ... . The research was conducted ... in Europe (KIHDNEy) Cohort ...
(Date:5/30/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with ... be presenting at the 7th annual LD Micro Invitational on Tuesday, ... CEO, of DarioHealth will be giving the presentation and meeting with ... & 7th, 2017 at the Luxe Sunset Bel Air Hotel and ... About LD Micro LD Micro was ...
Breaking Medicine Technology: